Lessons learned from Skylab are applied to methods of dealing with space sickness among crewmembers in their first orbital flight. Early experiences on Skylab 3 led to regularly scheduled scopalamine/dexedrine tablets ingestion. Subsequent experiences on the next Skylab mission established a 75% incidence of the sickness among first-time-in-orbit crewmembers, notably in periods of inactivity rather than work periods. Intramuscular injections are recommended to treat acute space sickness. Preflight transdermal scopalamine plus three or four doses of 5 mg amphetamine are chosen preventive measures, giving 12 hours of efficacy.
Coping with space motion sickness in Spacelab missions
1981-10-01
Miscellaneous
No indication
English
Spacelab experiments on space motion sickness
NTRS | 1985
|Spacelab experiments on space motion sickness
NTRS | 1987
|Space Motion Sickness and Vestibular Experiments in Spacelab
SAE Technical Papers | 1982
|NTRS | 1977
|